You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Dow
Express Scripts
Johnson and Johnson
Merck

Last Updated: February 26, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Gefapixant


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Gefapixant?

Gefapixant is an investigational drug.

There have been 10 clinical trials for Gefapixant. The most recent clinical trial was a Phase 2 trial, which was initiated on January 14th 2020.

The most common disease conditions in clinical trials are Cough, Common Cold, and Urinary Incontinence, Stress. The leading clinical trial sponsors are Merck Sharp & Dohme Corp., Afferent Pharmaceuticals, Inc., and [disabled in preview].

There are fourteen US patents protecting this investigational drug and one hundred and twenty international patents.

Recent Clinical Trials for Gefapixant
TitleSponsorPhase
Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042)Merck Sharp & Dohme Corp.Phase 3
Efficacy and Safety of Gefapixant (MK-7264) in Adult Participants With Recent Onset Chronic Cough (MK-7264-043)Merck Sharp & Dohme Corp.Phase 3
A Study of Gefapixant (MK-7264) in Japanese Adult Participants With Refractory or Unexplained Chronic Cough (MK-7264-038)Merck Sharp & Dohme Corp.Phase 3

See all Gefapixant clinical trials

Clinical Trial Summary for Gefapixant

Top disease conditions for Gefapixant
Top clinical trial sponsors for Gefapixant

See all Gefapixant clinical trials

US Patents for Gefapixant

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Gefapixant   Start Trial Methods and compositions for treating diseases and conditions Afferent Pharmaceuticals, Inc. (San Mateo, CA)   Start Trial
Gefapixant   Start Trial Substituted pyrimidines for treatment of chronic cough, neuronal hypersensitivity underlying chronic cough, neuronal hypersensitivity underlying sub-acute cough and neuronal hypersensitivity underlying acute cough Afferent Pharmaceuticals, Inc. (San Mateo, CA)   Start Trial
Gefapixant   Start Trial Diaminopyrimidines as P2X.sub.3 and P2X.sub.2/3 antagonists Roche Palo Alto LLC (Palo Alto, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Gefapixant

Drugname Country Document Number Estimated Expiration Related US Patent
Gefapixant European Patent Office 3164132 2034-07-03   Start Trial
Gefapixant World Intellectual Property Organization (WIPO) 2016004358 2034-07-03   Start Trial
Gefapixant Australia 2014308606 2033-08-23   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Mallinckrodt
AstraZeneca
Moodys
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.